Cell Therapeutics, GKV-SV Reach Agreement On Pixuvri Pricing In Germany

(RTTNews) - Cell Therapeutics, Inc. (CTIC) Wednesday said it concluded an agreement with the National Association of Statutory Health Insurance Funds, GKV-Spitzenverband, in Germany for Pixuvri or pixantrone.

Pixuvri is the first medicinal product approved in the European Union for patients with aggressive B-cell non-Hodgkin lymphoma or NHL who have failed two or three prior lines of therapy.

James Bianco, President and Chief Executive Officer, said, "We are pleased to have reached an agreement with the GKV-SV on the reimbursement price of 'PIXUVRI so that hematologists in Germany may continue to treat patients with the only approved treatment for this aggressive disease."

The drug is already available in Germany for healthcare professionals to prescribe in accordance with local guidance. In May 2012, the European Commission granted conditional marketing authorization for it as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive NHL.